对内皮氧化合成酶功能障碍和氧化替代疗法的药理向
Huige Li1, Ulrich Förstermann2, Ning Xia2
1Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz.
心血管风险因素对全球的健康造成重大负担. 针对内皮功能障碍,特别是氧化通路,为血管健康和疾病预防提供了有前途的治疗策略.
科学领域:
- 心血管研究的心血管研究.
- 血管生物学 血管生物学
- 氧化应激机制 氧化应激机制
背景情况:
- 心血管疾病是全球死亡和残疾的主要原因.
- 由氧化应激驱动的内皮功能障碍是动脉样硬化的早期指标.
- 缺陷的氧化合成酶 (eNOS) 功能是内皮功能障碍的核心.
研究的目的:
- 审查内皮质功能障碍的潜在治疗点.
- 突出药理学策略,以提高血管完整性和稳定性.
- 讨论未来治疗心血管疾病的方向.
主要方法:
- 关于内皮功能障碍研究近期进展的文献综述.
- 在氧化信号通路内的分子点的分析.
- 探索药理利用策略的研究.
主要成果:
- 内皮功能障碍是心血管疾病的关键病理机制.
- eNOS功能和下游信号是关键目标.
- 几种分子标显示出治疗干预的潜力.
结论:
- 针对eNOS及其信号通路对于治疗心血管疾病至关重要.
- 药理学策略为血管健康提供了有希望的途径.
- 未来的治疗应该考虑新的目标和生活方式的改变.
更多相关视频
08:58En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
相关概念视频
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
